Access the full text.
Sign up today, get DeepDyve free for 14 days.
Maemondo (2010)
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med, 362
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Journal of the National Cancer Institute, 97 5
Sreenath Sharma, D. Bell, J. Settleman, D. Haber (2007)
Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 7
F. Ciardiello, G. Tortora (2008)
EGFR antagonists in cancer treatment.The New England journal of medicine, 358 11
S. Simonetti, M. Molina, C. Queralt, I. Aguirre, C. Mayo, J. Bertran-Alamillo, J. Sánchez, J. González-Larriba, U. Jiménez, D. Isla, T. Morán, S. Viteri, C. Camps, R. García-Campelo, B. Massutí, S. Benlloch, S. Cajal, M. Taron, R. Rosell (2010)
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancerJournal of Translational Medicine, 8
(2011)
National Comprehensive Cancer Network. NCCN Guidelines: Non-Small Cell Lung Cancer, Version 2
Y. Kato, N. Peled, M. Wynes, Koichi Yoshida, M. Pardo, C. Mascaux, T. Ohira, M. Tsuboi, J. Matsubayashi, T. Nagao, N. Ikeda, F. Hirsch (2010)
Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor MutationsJournal of Thoracic Oncology, 5
T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima, K. Asami, N. Katakami, M. Takada, H. Yoshioka, K. Shibata, S. Kudoh, E. Shimizu, H. Saito, S. Toyooka, K. Nakagawa, M. Fukuoka (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.The Lancet. Oncology, 11 2
F. Janku, D. Stewart, R. Kurzrock (2010)
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?Nature Reviews Clinical Oncology, 7
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
A. Kawahara, K. Azuma, A. Sumi, T. Taira, Kazutaka Nakashima, E. Aikawa, H. Abe, Tomohiko Yamaguchi, S. Takamori, J. Akiba, M. Kage (2011)
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.Lung cancer, 74 1
(2001)
Pleural Diseases. 4th ed
R. Pirker, F. Herth, K. Kerr, M. Filipits, M. Taron, D. Gandara, F. Hirsch, D. Grunenwald, H. Popper, E. Smit, M. Dietel, A. Marchetti, C. Manegold, P. Schirmacher, Michael Thomas, R. Rosell, F. Cappuzzo, R. Stahel (2010)
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European WorkshopJournal of Thoracic Oncology, 5
Jian Yu, S. Kane, Jiong Wu, E. Benedettini, Dai-qiang Li, C. Reeves, Gregory Innocenti, Randy Wetzel, K. Crosby, A. Becker, Michelle Ferrante, W. Cheung, Xiqiang Hong, L. Chirieac, L. Sholl, H. Haack, Bradley Smith, R. Polakiewicz, Yi Tan, T. Gu, M. Loda, Xinmin Zhou, M. Comb (2009)
Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung CancerClinical Cancer Research, 15
P. Fetsch, A. Abati (2001)
Immunocytochemistry in effusion cytology: a contemporary review.Cancer, 93
Duykhanh Pham, M. Kris, Gregory Riely, I. Sarkaria, T. McDonough, S. Chuai, E. Venkatraman, V. Miller, M. Ladanyi, W. Pao, R. Wilson, Bhuvanesh Singh, V. Rusch (2006)
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 11
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
L. Tanoue (2010)
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerYearbook of Pulmonary Disease, 2010
A. Ladd, Emerald O’Sullivan-Mejia, T. Lea, Jessica Perry, C. Dumur, E. Dragoescu, C. Garrett, C. Powers (2011)
Preservation of fine‐needle aspiration specimens for future use in RNA‐based molecular testingCancer Cytopathology, 119
U. Malapelle, Claudio Bellevicine, P. Zeppa, L. Palombini, G. Troncone (2011)
Cytology‐based gene mutation tests to predict response to anti‐epidermal growth factor receptor therapy: A reviewDiagnostic Cytopathology, 39
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
Mok (2009)
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med, 361
D. Eberhard, G. Giaccone, B. Johnson (2008)
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 6
Yoshiki Kozu, K. Tsuta, T. Kohno, I. Sekine, A. Yoshida, Shun-ichi Watanabe, T. Tamura, J. Yokota, Kenji Suzuki, H. Asamura, K. Furuta, H. Tsuda (2011)
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.Lung cancer, 73 1
Donghui Li, Jeffrey Morris, Jun Liu, Manal Hassan, R. Day, Melissa Bondy, J. Abbruzzese (2009)
F1000 highlightsAsia‐Pacific Journal of Clinical Oncology, 5
S. D’Angelo, M. Pietanza, M. Johnson, Gregory Riely, V. Miller, C. Sima, M. Zakowski, V. Rusch, M. Ladanyi, M. Kris (2011)
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15
A. Kawahara, C. Yamamoto, Kazutaka Nakashima, K. Azuma, S. Hattori, Masaki Kashihara, H. Aizawa, Y. Basaki, M. Kuwano, M. Kage, T. Mitsudomi, M. Ono (2010)
Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical AnalysisClinical Cancer Research, 16
V. Keedy, S. Temin, M. Somerfield, M. Beasley, David Johnson, L. McShane, D. Milton, John Strawn, H. Wakelee, G. Giaccone (2011)
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15
Haruhiko Nakamura, A. Mochizuki, T. Shinmyo, K. Ando, N. Kurimoto, K. Yokote, M. Takagi (2010)
Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma.Anticancer research, 30 12
S-G. Wu, C. Gow, C-J. Yu, Y-L. Chang, C-H Yang, Yi-Chiung Hsu, J. Shih, Y-C Lee, P. Yang (2008)
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinomaEuropean Respiratory Journal, 32
M. Tattersall, Michael Boyer (1990)
Management of malignant pleural effusions.Thorax, 45
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proceedings of the National Academy of Sciences of the United States of America, 101 36
Lin Huan (2010)
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerJournal of Evidence-based Medicine
M. Salto‐Tellez, M. Tsao, J. Shih, S. Thongprasert, Shun Lu, G. Chang, J. Au, T. Chou, Jong-Seok Lee, Yuankai Shi, A. Radzi, Jin-Hyoung Kang, Sang-We Kim, S. Tan, Jie Yang (2011)
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological ApproachJournal of Thoracic Oncology, 6
Tzu-Hsiu Tsai, K. Su, S-G. Wu, Y-L. Chang, S-C. Luo, I. Jan, C-J. Yu, S-L Yu, J. Shih, P. Yang (2011)
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancerEuropean Respiratory Journal, 39
P. Fetsch, A. Abati (2001)
Immunocytochemistry in effusion cytologyCancer Cytopathology, 93
E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel (2011)
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.Annals of oncology : official journal of the European Society for Medical Oncology, 22 7
A. Kitamura, W. Hosoda, E. Sasaki, T. Mitsudomi, Y. Yatabe (2010)
Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung CancerClinical Cancer Research, 16
M. Brevet, M. Arcila, M. Ladanyi (2010)
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR.The Journal of molecular diagnostics : JMD, 12 2
o RIGINAL ARTICLE Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai, MD,* Shang-Gin Wu, MD,† Yih-Leong Chang, MD,‡ Chen-Tu Wu, MD,‡ Meng-Feng Tsai, PhD,§ Pin-Fei Wei, MS,|| Chih-Hsin Yang, MD, PhD,¶ Chong-Jen Yu, MD, PhD,* Pan-Chyr Yang, MD, PhD,*# and Jin-Yuan Shih, MD, PhD* Results: of the 78 MPE samples, direct sequencing using cell-derived Introduction: Tumor tissue is often not obtainable or suitable for RNA identified L858R mutation in 42 cases, deletions in exon 19 in molecular-based epidermal growth factor receptor (EGFR) muta- 12 cases (delE746-A750 in eight cases), other types of mutations tional analysis in advanced non–small-cell lung cancer (NSCLC). in three cases, and wild-type EGFR in 21 cases. Effusion immuno- This retrospective and single-institution study was conducted to cytochemistry with these two mutant-specific antibodies exhibited evaluate the role of effusion immunocytochemistry using two EGFR a sensitivity of 71% and 88% and a specificity of 86% and 96% for mutant-specific antibodies for the detection of relevant EGFR muta- identifying predefined L858R and delE746-A750 mutations, respec - tions in NSCLC, along with the selection of candidates for first-line tively. Effusion immunocytochemistry provided a superior prediction therapy with EGFR
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Jun 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.